Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

29.63 +0.63 (+2.17%)

Delayed Quote Updated: 11:57 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

61 62 Next >

3 Market-Beating Stocks to Research Further

April 24, 2026

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...

Via StockStory

Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program ↗

April 21, 2026

Telehealth investors weigh Amazon’s new anti-obesity drug push against this platform’s recent rapid growth, today, April 21, 2026.

Via The Motley Fool

Topics Stocks

A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗

April 21, 2026

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

Via The Motley Fool

What's Going On With Hims & Hers Shares ↗

April 17, 2026

Shares of Hims & Hers Health Inc. (NASDAQ: HIMS) are rising Friday on the momentum from U.S. drug regulators easing restrictions on peptides.

Via Benzinga

Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies ↗

April 16, 2026

On April 16, 2026, investors monitored an FDA peptide review that could be a boost to Hims & Hers Health.

Via The Motley Fool

Topics Stocks

Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks

April 15, 2026

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peer...

Via StockStory

Hims & Hers to Announce First Quarter 2026 Financial Results on May 11, 2026

April 13, 2026

From Hims & Hers

Via Business Wire

Did Hims & Hers Just Become an AI Company? ↗

April 10, 2026

Artificial intelligence could be a big differentiator for Hims & Hers.

Via The Motley Fool

Topics Artificial Intelligence

2 Profitable Stocks with Exciting Potential and 1 We Ignore

April 10, 2026

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Via StockStory

3 Sectors to Buy While They're Down and 1 to Walk Away From ↗

April 07, 2026

When the S&P 500 was flirting with 7,000 back in January, everyone wanted in. Now, with the index 400 to 500 points lower, the mood has flipped to fear. That disconnect between price and psychology is...

Via MarketBeat

Topics Stocks

Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS

April 03, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Should You Buy Hims Stock Today? ↗

April 02, 2026

The healthcare industry is ripe for disruption, and Hims is making early progress in this effort.

Via The Motley Fool

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

Via StockStory

Topics Government Stocks World Trade

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

April 01, 2026

From Schall Law

Via GlobeNewswire

Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know

March 27, 2026

What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in...

Via StockStory

Topics Government Stocks

2 Mooning Stocks on Our Buy List and 1 Facing Challenges

March 27, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

Via StockStory

Topics Initial Public Offering

What's Happening With Novo Nordisk Stock Today? ↗

March 26, 2026

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the...

Via Benzinga

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers

March 26, 2026

From Hims & Hers

Via Business Wire

Surging Oil Prices Spark Market Jitters ↗

March 25, 2026

The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring.

Via The Motley Fool

Topics Artificial Intelligence Economy Stocks

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm

March 25, 2026

From Schall Law

Via GlobeNewswire

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

March 23, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

Via StockStory

This Hims & Hers Move Could Destroy Competitors ↗

March 21, 2026

The Wegovy pill could change Hims & Hers' growth in 2026.

Via The Motley Fool

Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗

March 20, 2026

The healthcare stock has lost more than half of its value in the past year.

Via The Motley Fool

1 Growth Stock with All-Star Potential and 2 That Underwhelm

March 19, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal ↗

March 18, 2026

Hims & Hers Health, Inc. (NYSE:HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to

Via Benzinga

Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot

March 18, 2026

As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year...

Via Finterra

Topics Intellectual Property

Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗

March 18, 2026

The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform.

Via Stocktwits

Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗

March 17, 2026

These companies are benefiting from a tidal wave of demand for new weight-loss drugs.

Via The Motley Fool

Topics Stocks

Hims & Hers Health Stock Slips After Surging 50% In A Month ↗

March 16, 2026

Hims & Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally.

Via Benzinga

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗

March 16, 2026

The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.

Via The Motley Fool

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

61 62 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.